Pituitary

, Volume 14, Issue 4, pp 418–424 | Cite as

Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor

  • Marie S. Thearle
  • Pamela U. Freda
  • Jeffrey N. Bruce
  • Steven R. Isaacson
  • Yoomi Lee
  • Robert L. Fine
Article

Abstract

Only rarely do corticotroph pituitary tumors become invasive leading to symptoms caused by compression of cranial nerves and other local structures. When aggressive pituitary neuroendocrine tumors do develop, conventional treatment options are of limited success. A 50-year-old man developed a giant invasive corticotroph pituitary tumor 2 years after initial presentation. His tumor and symptoms failed to respond to maximal surgical, radio-surgical, radiation and medical therapy and a bilateral adrenalectomy was done. He subsequently developed rapid growth of his tumor leading to multiple cranial nerve deficits. He was administered salvage chemotherapy with capecitabine and temozolomide (CAPTEM), a novel oral chemotherapy regimen developed at our institution for treatment of neuroendocrine tumors. After two cycles of CAPTEM, his tumor markedly decreased in size and ACTH levels fell by almost 90%. Despite further decreases in ACTH levels, his tumor recurred after 5 months with increased avidity on PET scan suggesting a transformation to a more aggressive phenotype. Temozolomide had been reported to be effective against other pituitary tumors and this case adds to this literature demonstrating its use along with capecitabine (CAPTEM) against a corticotroph tumor. Further evaluation of the CAPTEM regimen in patients with pituitary neuroendocrine tumors which fail to respond to classic treatments is warranted.

Notes

Acknowledgments

Presented at Marie S. Thearle, Pamela U. Freda, Jeffrey N. Bruce, Steven R. Isaacson, Yoomi Lee and Robert L. Fine.. The use of Temozolomide (Temodar®) and Capecitabine (Xeloda®) for treatment of an aggressive corticotroph pituitary tumor. 89th Annual Meeting of the Endocrine Society, OR. Toronto, Canada, June, 2007. Supported in part by DK073040 (to PUF).

References

  1. 1.
    Lubke D, Saeger W, Ludecke DK (1995) Proliferation markers and EGF in ACTH-secreting adenomas and carcinomas of the pituitary. Endocr Pathol 6:45–55PubMedCrossRefGoogle Scholar
  2. 2.
    Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90:3089–3099PubMedCrossRefGoogle Scholar
  3. 3.
    Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE (2006) Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105:621–626PubMedCrossRefGoogle Scholar
  4. 4.
    Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38:185–189PubMedCrossRefGoogle Scholar
  5. 5.
    Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7:518–520PubMedCrossRefGoogle Scholar
  6. 6.
    Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. PituitaryGoogle Scholar
  7. 7.
    Hagen C, Schroeder H, Hansen S, Andersen M (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J EndocrinolGoogle Scholar
  8. 8.
    McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ (2009) Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71:226–233CrossRefGoogle Scholar
  9. 9.
    Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD (2009) Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64:E773–E774 Discussion E774PubMedCrossRefGoogle Scholar
  10. 10.
    Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804–812PubMedCrossRefGoogle Scholar
  11. 11.
    Kontogeorgos G (2006) Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83:179–188PubMedCrossRefGoogle Scholar
  12. 12.
    Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing’s disease: A reappraisal of Nelson’s syndrome. J Clin Endocrinol Metab 92:172–179PubMedCrossRefGoogle Scholar
  13. 13.
    Jenkins PJ, Trainer PJ, Plowman PN, Shand WS, Grossman AB, Wass JA, Besser GM (1995) The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab 80:165–171PubMedCrossRefGoogle Scholar
  14. 14.
    van der Hoek J, Lamberts SW, Hofland LJ (2004) The role of somatostatin analogs in Cushing’s disease. Pituitary 7:257–264PubMedCrossRefGoogle Scholar
  15. 15.
    Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W (1980) Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98:617–638PubMedGoogle Scholar
  16. 16.
    Salgado LR, Machado MC, Cukiert A, Liberman B, Kanamura CT, Alves VA (2006) Cushing’s disease arising from a clinically nonfunctioning pituitary adenoma. Endocr Pathol 17:191–199PubMedCrossRefGoogle Scholar
  17. 17.
    Tan EU, Ho MS, Rajasoorya CR (2000) Metamorphosis of a non-functioning pituitary adenoma to Cushing’s disease. Pituitary 3:117–122PubMedCrossRefGoogle Scholar
  18. 18.
    Raffin-Sanson ML, Massias JF, Dumont C, Raux-Demay MC, Proeschel MF, Luton JP, Bertagna X (1996) High plasma proopiomelanocortin in aggressive adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab 81:4272–4277PubMedCrossRefGoogle Scholar
  19. 19.
    Ambrosi B, Dall’Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Peccoz P (2004) Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing’s disease. Eur J Endocrinol 151:173–178PubMedCrossRefGoogle Scholar
  20. 20.
    Andreassen M, Kristensen LO (2005) Rosiglitazone for prevention or adjuvant treatment of Nelson’s syndrome after bilateral adrenalectomy. Eur J Endocrinol 153:503–505PubMedCrossRefGoogle Scholar
  21. 21.
    Heaney AP, Fernando M, Melmed S (2003) PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 111:1381–1388PubMedGoogle Scholar
  22. 22.
    Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB (2006) The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson’s syndrome. Clin Endocrinol (Oxf) 64:519–522CrossRefGoogle Scholar
  23. 23.
    Amatori F, Di Paolo A, Del Tacca M, Fontanini G, Vannozzi F, Boldrini L, Bocci G, Lastella M, Danesi R (2006) Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Pharmacogenet Genomics 16:809–816PubMedCrossRefGoogle Scholar
  24. 24.
    Isacoff WH Moss RA, Pecora AL, Fine RL 2006 Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. J Clin Oncol, ASCO Annual meeting proceedings part I 24:14023Google Scholar
  25. 25.
    FD FineRL, Schreibman SM (2005) Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. J Clin Oncol, ASCO Annual meeting proceedings 23:4216Google Scholar
  26. 26.
    Widhalm G, Wolfsberger S, Preusser M, Woehrer A, Kotter MR, Czech T, Marosi C, Knosp E (2009) O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer 115:1070–1080PubMedCrossRefGoogle Scholar
  27. 27.
    Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115:261–262PubMedCrossRefGoogle Scholar
  28. 28.
    Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS (2009) O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15:338–345PubMedCrossRefGoogle Scholar
  29. 29.
    Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, Broglio K, Yin G, Hortobagyi GN, Buchholz T (2006) Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107:1348–1354PubMedCrossRefGoogle Scholar
  30. 30.
    Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406PubMedCrossRefGoogle Scholar
  31. 31.
    Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP, Plowman PN, Drake WM (2009) Treatment of Nelson’s syndrome with temozolomide. Eur J Endocrinol 160:115–119PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Marie S. Thearle
    • 1
  • Pamela U. Freda
    • 1
    • 5
  • Jeffrey N. Bruce
    • 2
  • Steven R. Isaacson
    • 3
  • Yoomi Lee
    • 4
  • Robert L. Fine
    • 1
    • 4
  1. 1.Department of Medicine, Division of Medical OncologyColumbia University College of Physicians and SurgeonsNew YorkUSA
  2. 2.Department of Neurosurgery, Division of Medical OncologyColumbia University College of Physicians and SurgeonsNew YorkUSA
  3. 3.Department of Radiation Oncology, Division of Medical OncologyColumbia University College of Physicians and SurgeonsNew YorkUSA
  4. 4.Experimental Therapeutics Program, Division of Medical OncologyColumbia University College of Physicians and SurgeonsNew YorkUSA
  5. 5.Department of Medicine, Division of EndocrinologyColumbia University College of Physicians and SurgeonsNew YorkUSA

Personalised recommendations